5 unknown, 3 recruiting, 1 active not recruiting, 1 completed. 12 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 12 | Unknown 5, Recruiting 3, Active not recruiting 1, Completed 1, Enrolling by invitation 1, Not yet recruiting 1 |
| Phase 2 | 3 | Unknown 3 |
Follow Chidamide: new trials by email Literature Review of Chidamide trials Research Report on Chidamide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Chidamide Maintenance to Prevent Relapse After Allogeneic Hematopoietic Stem Cell Transplantation in Acute T-Lymphoblastic Leukemia/Lymphoma Chidamide, Control Group - T-Cell Acute Lymphoblastic Leukemia, T-Cell Lymphoblastic Lymphoma | Phase 3 | Not yet recruiting | First Affiliated Hospital of Zhejiang University | 132 | 2026-08-15 | 2026-08-19 |
| Chidamide for Maintenance Treatment of HBV-infected Diffuse DLBCL in Patients Initially Treated With R-CHOP Chidamide, Entecavir Tablets - Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 3 | Recruiting | Ou Bai, MD/PHD | 200 | 2026-05-30 | 2026-03-25 |
| A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients Tucidinostat, Sintilimab, Bevacizumab - Colorectal Cancer | Phase 3 | Recruiting | Chipscreen Biosciences, Ltd. | 430 | 2024-12-06 | 2026-03-19 |
| A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19) Golidocitinib, Chidamide, Gemcitabine - Peripheral T-cell Lymphoma | Phase 3 | Recruiting | Dizal Pharmaceuticals | 218 | 2024-05-13 | 2026-06-08 |
| AC-CHOP Versus CHOP in Patients With Previously Untreated PTCL-TFH Azacitidine, Chidamide, Cyclophosphamide - Peripheral T-cell Lymphoma Targeted Therapy | Phase 3 | Enrolling by invitation | Tianjin Medical University Cancer Institute and Hospital | 200 | 2023-01-01 | 2023-01-10 |
| ChiCGB vs BEAM in High-risk or R/R Lymphomas Chidamide, Cladribine, Gemcitabine - Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell | Phase 3 | Unknown | Sichuan University | 306 | 2022-07-01 | 2022-07-25 |
| Clinical Study of Mitoxantrone Hydrochloride Liposome Injection vs. Chidamide in Patients With Relapsed/Refractory PTCL Mitoxantrone Hydrochloride Liposome Injection, Chidamide - Peripheral T Cell Lymphoma | Phase 3 | Active not recruiting | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 193 | 2021-04-13 | 2025-05-31 |
| Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients chidamide, cyclophosphamide, liposomal doxorubicin - Peripheral T Cell Lymphoma | Phase 3 | Unknown | Nanfang Hospital, Southern Medical University | 174 | 2017-02-01 | 2017-01-18 |
| Precision Diagnosis Directing HDACi and TKI Target Therapy for Adult Ph-like ALL Chidamide, Dasatinib - Leukemia, Leukemia, Acute | Phase 2 / Phase 3 | Unknown | Nanfang Hospital, Southern Medical University | 120 | 2016-02-14 | 2022-07-01 |
| Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult T-LBL/ALL Dexamethasone, vincristine, Cyclophosphamide - Leukemia, Leukemia, Acute | Phase 2 / Phase 3 | Unknown | Nanfang Hospital, Southern Medical University | 80 | 2016-02-14 | 2018-06-21 |
| Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult ETP-ALL Chidamide, Dexamethasone, vincristine - Leukemia, Acute, Leukemia, T Cell | Phase 2 / Phase 3 | Unknown | Nanfang Hospital, Southern Medical University | 70 | 2016-02-14 | 2018-06-12 |
| Trial of Chidamide in Combination With Exemestane in Patients With Advanced Breast Cancer Chidamide, exemestane, placebo - Breast Cancer | Phase 3 | Completed | Chipscreen Biosciences, Ltd. | 365 | 2015-07-01 | 2022-01-12 |
Leukemia (3) · Lymphoma, T-Cell, Peripheral (3) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (3) · Leukemia, T-Cell (2) · Lymphoma, Large B-Cell, Diffuse (2) · Breast Neoplasms (1) · Colorectal Neoplasms (1) · Leukemia, B-Cell (1) · Lymphoma, T-Cell (1) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (1)
Nanfang Hospital, Southern Medical University (4) · Chipscreen Biosciences, Ltd. (2) · CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (1) · Dizal Pharmaceuticals (1) · First Affiliated Hospital of Zhejiang University (1) · Ou Bai, MD/PHD (1) · Sichuan University (1) · Tianjin Medical University Cancer Institute and Hospital (1)
China (11) · Taiwan (1) · Thailand (1)
Hongsheng Zhou, MD, PhD (1) · Ou Bai, PHD (1) · Qifa Liu, MD (1) · Ru Feng, M.D. (1) · Rui-Hua Xu (1) · Yanmin Zhao, MD (1) · Zefei Jiang (1)